Clinical Trial Update: An Immuno-bridging Study of a Nonavalent HPV Vaccine (E.Coli) in Healthy Population Aged 9-17 vs Aged 18-26 Years Old [Phase 3]

View source ↗

Summary

A Phase 3 immuno-bridging study of a nonavalent HPV vaccine expressed in E. coli is comparing immune responses between healthy participants aged 9-17 and 18-26;…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cervical Cancer
• Condyloma Acuminata

Drugs mentioned

• Nonavalent HPV vaccine (E.Coli) (HPV vaccine, nonavalent)

Snippet

Sponsor: Xiamen University | Conditions: Cervical Cancer, Condylomata Acuminata | Phase 3 | Status: ACTIVE_NOT_RECRUITING